Shengjie Dai
- Urology top 10%
-
- MicroRNA in disease regulation 4
- Cancer-related molecular mechanisms research 4
-
- Pancreatic and Hepatic Oncology Research 5
- Cancer Cells and Metastasis 3
-
- RNA modifications and cancer 5
-
- Pancreatitis Pathology and Treatment 4
- Cholangiocarcinoma and Gallbladder Cancer Studies 3
-
- Hepatocellular Carcinoma Treatment and Prognosis 3
- Cited by
- UrologyCancer ResearchOncology
- Journals
- Journal of Clinical Oncology (1 paper)Clinical Cancer Research (1 paper)Frontiers in Immunology (1 paper)
- Partner nations
- ChinaUnited StatesIndonesia
In The Last Decade
Shengjie Dai
31 papers receiving 434 citations
Peers
Comparison fields: 5 of 74
- Urology 51
- Cancer Research 105
- Oncology 103
- Biochemistry 21
- Molecular Biology 206
Countries citing papers authored by Shengjie Dai
This map shows the geographic impact of Shengjie Dai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shengjie Dai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shengjie Dai more than expected).
Fields of papers citing papers by Shengjie Dai
This network shows the impact of papers produced by Shengjie Dai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shengjie Dai. The network helps show where Shengjie Dai may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Shengjie Dai, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 2 | |
| 2 | 2024 | 7 | |
| 3 | 2024 | 3 | |
| 4 | 2023 | 4 | |
| 5 | 2023 | 15 | |
| 6 | 2023 | 10 | |
| 7 | 2022 | 15 | |
| 8 | 2022 | 4 | |
| 9 | 2022 | 4 | |
| 10 | 2021 | 7 | |
| 11 | 2021 | 13 | |
| 12 | 2019 | 16 | |
| 13 | 2019 | 8 | |
| 14 | 2018 | 32 | |
| 15 | 2017 | 54 | |
| 16 | 2016 | 31 | |
| 17 | 2016 | 29 | |
| 18 | 2015 | 78 | |
| 19 | 2015 | 9 | |
| 20 | 2014 | 29 |
About Shengjie Dai
Shengjie Dai is a scholar working on Cancer Research, Oncology and Hepatology, having authored 31 papers that have together received 437 indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (5 papers), RNA modifications and cancer (5 papers), MicroRNA in disease regulation (4 papers), Pancreatitis Pathology and Treatment (4 papers), Cancer-related molecular mechanisms research (4 papers), Cancer Cells and Metastasis (3 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (3 papers) and Hepatocellular Carcinoma Treatment and Prognosis (3 papers). The work is most often cited by research in Urology (51 citations), Cancer Research (105 citations) and Oncology (103 citations). Shengjie Dai has collaborated with scholars based in China, United States and Indonesia. Frequent co-authors include Mengtao Zhou, Xince Huang, Bicheng Chen, Hongru Kong, Hongwei Sun, Juji Dai, Bicheng Chen, Yongyu Bai, Shihao Huang and Tingting Ye. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research and Frontiers in Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.